Tabela 1. Socio-demographic characteristics of respondents

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | **N(%)** | **Arithmetric mean** | **SD** | **Max/min** | **Median** | **Male N (%)** | **Female N (%)** |
| **Gender** |  |  |  |  |  |  |  |
| Male | 119 (50) |  |  |  |  |  |  |
| Female | 119 (50) |  |  |  |  |  |  |
| **Age** |  | 73.4 | 10.35 | 31-94 | 74 |  |  |
| ≤ 64 | 36 (15.1) |  |  |  |  | 21 (17.6) | 15 (12.6) |
| 65-74 | 86 (36.1) |  |  |  |  | 45 (37.8) | 41 (34.5) |
| 75-84 | 80 (33.6) |  |  |  |  | 37 (31.1) | 43 (36.1) |
| ≥ 85 | 36 (15.1) |  |  |  |  | 16 (13.4) |  |
| **Level of education** |  |  |  |  |  |  |  |
| Primary school | 29 (12.2) |  |  |  |  |  |  |
| Secondary school | 156 (65.5) |  |  |  |  |  |  |
| Community college | 38 (16) |  |  |  |  |  |  |
| University degree | 12 (5) |  |  |  |  |  |  |
| **Working status** |  |  |  |  |  |  |  |
| retired | 202 (84.9) |  |  |  |  |  |  |
| Employed | 2.9 (12.2) |  |  |  |  |  |  |
| unemployed | 7 (2.9) |  |  |  |  |  |  |

Tabela 2. Anticoagulant therapy prescription in relation to the age and gender

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Anticoagulant drug group** | N | % | Age (N/%) | | | | p value | Gender | | p value |
| ≤64 | 65-74 | 75-84 | ≥85 | Female N (%) | Male N (%) |
| **NOAC** | 70 | 29.4 | 8 | 28 | 25 | 9 |  | 37 | 33 |  |
| (11.4) | (40) | (35.7) | (12.9) |  | (52.9) | (47.1) |  |
| **VKA** | 105 | 44.1 | 13 | 39 | 32 | 21 | 0.6 | 57 | 48 | 0.8 |
| (12.4) | (58.2) | (30.5) | (20) |  | (54.3) | (45.7) |  |
| **Overall** | 175 | 73.5 | 21 | 67 | 57 | 30 |  | 94 | 81 |  |
| (12) | (38.3) | (32.6) | (17.1) |  | (53.7) | (46.3) |  |
| **NO therapy** | 63 | 26.5 |  |  |  |  |  |  |  |  |

Tabela 3. Distribution of CHA2DS2-VASc and anticoagulants prescribing scores in relation to age and gender

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **CHA2DS2-VASc** | **Frequency** | **Percentage** | **Cumulative percentage** | **Frequency** | **Percentage** | **Patients without anticoagulant therapy** | |
|  |  |  |  | **CHA2DS2-VASc** | | | |
|  |  |  |  | **1** | **≥2** | **1** | **≥2** |
| 0 | 6 | 2.5 | 2.5 |  |  | 5 (8.5) | 54 (91.5) |
| 1 | 13 | 5.5 | 8.0 | 13 | 5.5 |
| 2 | 30 | 12.6 | 20.6 | 219 | 92.0 |
| 3 | 84 | 35.3 | 55.9 |
| 4 | 76 | 31.9 | 87.8 |
| 5 | 22 | 9.2 | 97.1 |
| 6 | 6 | 2.5 | 99.6 |
| 7 | 1 | 0.4 | 100.0 |
| Overall | 238 | 100.0 |  | 232 | 97.5 |
| **Age** | | | | **Anticoagulant drugs** | | | |
|  | **CHA2DS2-VASc** | |  |  | **CHA2DS2-VASc** | |  |
|  | **1** | **≥2** | **p value** |  | **1** | **≥2** | **p value** |
| ≤64 | 10 (33.3) | 20 (66.7) | 0.0 | NOAC | 3 (4.3) | 67 (95.7) | 0.5 |
|
| 65-74 | 1 (1.2) | 85 (98.8) |
| VAK | 5 (4.9) | 98 (95.1) |
| 75-84 | 1 (1.3) | 79 (98.7) |
|
| ≥85 | 1 (2.8) | 35 (97.2) | Overall | 8 (4.6) | 165 (95.4) |
|
|  |  |  |

Tabela 4. Presentation of the regulation of INR values ​​in relation to the age and gender

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **INR** | | N (%) | Midpoint | | SD | Max | Min |
| **patients** | | 107 | 2,3 | | 0.86 | 7,06 | 0.99 |
| **INR** | age | | | | gender | | Overall |
| <64 | 65-74 | 75-84 | >85 | male | female |
| **Unregulated** | 5 (9.6) | 12 (23.1) | 24 (46.2) | 11 (21.2) | 25 (48.1) | 27 (51.9) | 52 (100) |
| **Regulated** | 5 (9.1) | 25 (45.5) | 13 (23.6) | 12 (21.8) | 32 (58.2) | 23 (41.8) | 55 (100) |
| **Overall** | 10 (9.3) | 37 (34.6) | 37 (34.6) | 23 (21.5) | 57 (53.3) | 50 (46.7) | 107 (100) |

Tabela 5. Display of INR values ​​in relation to the CHA2DS2VASc score

|  |  |  |  |
| --- | --- | --- | --- |
| **INR values** | CHA2DS2VASc skor N | | |
| 1 | ≥2 | p value |
| **Unregulated** | 3 | 47 | 0.5 |
| **Regulated** | 2 | 53 |

Tabela 6. Relationship between HAS BLED score and type of anticoagulant therapy

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **HAS BLED score** | Frequency | Percentage | Cumulative percentage | Anticoagulant drugs | | p |
| NOAC | VAK |
| 0 | 5 | 2.1 | 2.9 | 44 (41.9) | 61(58.1) | 0.5 |
| 1 | 23 | 9.7 | 16.0 |
| 2 | 77 | 32.4. | 60.0 |
| 3 | 57 | 23.9 | 92.6 | 26(37.1) | 44(62.9) |
| 4 | 11 | 4.6 | 98.9 |
| 5 | 2 | 0.8 | 100.0 |
| Total | 175 | 73.5 |  | 175 | |  |